Clinical characteristics and prognosis of different subtypes ofbreast cancer with bone metastasis
10.7652/jdyxb201705024
- VernacularTitle:不同分子亚型乳腺癌骨转移患者的临床特征和预后分析
- Author:
Anqi LUO
;
Rui HAN
;
Fang WU
;
Guanying WANG
;
Yujiao ZHANG
;
Xin JING
;
Xinhan ZHAO
- Keywords:
breast neoplasm;
bone metastasis;
subtype;
clinical characteristic;
prognosis
- From:
Journal of Xi'an Jiaotong University(Medical Sciences)
2017;38(5):740-743
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinicopathological characteristics and prognosis of different subtypes of breast cancer patients with bone metastasis.Methods For this study, we recruited 300 primary breast cancer patients with bone metastasis treated at the Department of Oncology, the First Affiliated Hospital of Xi`an Jiaotong University, between September 1, 2007 and September 1, 2011.We also retrospectively analyzed their clinical and follow-up data.Results The percentage of Luminal A, Luminal B, human epidermal growth factor receptor-2 (HER-2) overexpression and triple negative subtypes in all the bone metastatic breast cancer patients was 59.0％, 16.0％, 13.7％ and 11.3％, respectively.Age, tumor size and histologic grade significantly differed among the four subtypes (P<0.05).However, there were no significant differences in menopausal status, lymph node metastasis, histological type or lymphovascular invasion among different subtypes (P>0.05).The median survival time of Luminal A breast cancer patients with bone metastasis was 28.6 months, longer than Luminal B (26.9 months), HER-2 overexpression (20.9 months) and triple negative breast cancer patients (12.0 months) with bone metastasis.The overall survival significantly differed among the patients with four subtypes of breast cancer.Conclusion Different subtypes of breast cancer patients with bone metastasis have different clinical characteristics and prognosis.Luminal A breast cancer patients with bone metastasis have better prognosis whereas triple negative subtype has poorer prognosis.
